ACOR - Acorda Gets Much Needed FDA Approval To Counter Patent Setback
Recently, Acorda Therapeutics (ACOR) announced that it had received FDA approval for its inhaled levadopa treatment for patients with Parkinson's disease ((PD)). The FDA approval of INBRIJA will definitely help add revenue for the company. It won't be blockbuster status type revenue, but it will help a little in alleviating concern with its only other approved product Ampyra. It is expected that INBRIJA will be ready for prescription use in early 2019, which means patients won't have to wait long for desperately needed treatment.
FDA Approval
The FDA approval for INBRIJA is good